Here are the DEF 14A proxy statements from Zenas BioPharma, Inc. (ZBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ZBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBIO filings page.
Zenas BioPharma, Inc. will hold its 2026 Annual Meeting of Stockholders as a virtual-only event on May 11, 2026 at 8:00 a.m. Eastern Time. Stockholders of record as of March 12, 2026, when 57,371,044 common shares were outstanding, may participate and vote.
Two Class II directors, James Boylan and Patrick Enright, are nominated to serve until the 2029 annual meeting, while existing Class II director Tomas Kiselak will not stand for re‑election and the board will shrink by one seat. Stockholders are also asked to ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy describes board structure, committee responsibilities, director compensation and 2024–2025 pay for key executives, including CEO Leon O. Moulder Jr., President and COO Joseph L. Farmer, and Head of R&D and CMO Lisa von Moltke, M.D.